Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomised controlled trial

The Lancet

Volumn 383, Issue 9926, 2014, Pages 1395-1403

  Morrison, Anthony P ^a,d   Turkington, Douglas ^e,f   Pyle, Melissa ^a,d   Spencer, Helen ^e,f   Brabban, Alison ^g,h   Dunn, Graham ^b   Christodoulides, Tom ^f   Dudley, Rob ^e,f   Chapman, Nicola ^a,d   Callcott, Pauline ^f   Grace, Tim ^h   Lumley, Victoria ^h   Drage, Laura ^a,d   Tully, Sarah ^a,d   Irving, Kerry ^a,d   Cummings, Anna ^e,f   Byrne, Rory ^a,d   Davies, Linda M ^c   Hutton, Paul ^a,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Health Methodology Research Group   (United Kingdom)

^c Centre for Health Economics   (United Kingdom)

^d GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^g DURHAM UNIVERSITY   (United Kingdom)

^h The Royal College of Psychiatrists   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; FEASIBILITY STUDY; FEMALE; HOSPITAL ADMISSION; HUMAN; INTOXICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTSYNAPTIC POTENTIAL; PRIORITY JOURNAL; PSYCHOTIC SYMPTOM RATING SCALE; QUESTIONNAIRE ON THE PROCESS OF RECOVERY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; SOCIAL INTERACTION ANXIETY SCALE; CONTROLLED STUDY; DELUSIONAL DISORDER; SCHIZOAFFECTIVE PSYCHOSIS; TREATMENT OUTCOME;

NEUROLEPTIC AGENT;

ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; ENGLAND; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; QUESTIONNAIRES; SCHIZOPHRENIA; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 84898822349     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62246-1     Document Type: Article

References (38)

1. National Institute for Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. UK: NICE, 2009.
2. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-27.
3. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379: 2063-71.
4. Lieberman JA, Stroup TS, McEvoy JP, et al, and the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.
5. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-909.
6. MoncrieffJ, Cohen D, Mason JP. The subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009; 120: 102-11.
7. Morrison AP, Hutton P, Shiers D, Turkington D. Antipsychotics: is it time to introduce patient choice? Br J Psychiatry 2012; 201: 83-84.
8. Lepping P, Sambhi RS, Whittington R, Lane S, Poole R. Clinical relevance of findings in trials of antipsychotics: systematic review. Br J Psychiatry 2011; 198: 341-45.
9. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013; 382: 951-62.
10. Correll CU, De Hert M. Antipsychotics for acute schizophrenia: making choices. Lancet 2013; 382: 919-20.
11. Ho B-C, Andreasen NC, Ziebell S, Pierson R, Magnotta V. Longterm antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch Gen Psychiatry 2011; 68: 128-37.
12. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360: 225-35.
13. Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychoticinduced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry 2008; 193: 101-07.
14. Owens GS, Richardson G, David AS, Szmukler G, Hayward P, Hotopf M. Mental capacity to make decisions on treatment in people admitted to psychiatric hospitals: cross sectional study. BMJ 2008; 337: a448.
15. Warner L, Mariathasan J, Lawton-Smith S, Samele C. A Review of the literature and consultation on choice and decision-making for users and carers of mental health and social care services. London: King's Fund/Sainsbury Centre for Mental Health, 2006.
16. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008; 34: 523-37.
17. Morrison AP, Hutton P, Wardle M, et al. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial. Psychol Med 2012; 42: 1049-56.
18. Morrison AP, Wardle M, Hutton P, et al. Assessing cognitive therapy instead of neuroleptics: rationale, study design and sample characteristics of the ACTION trial. Psychosis 2013; 5: 82-92.
19. Ainsworth JD, Harper RS. The PsyGrid experience: using web services in the study of schizophrenia. Int J Healthc Inf Syst Inform 2007; 2: 1-20.
20. Morrison AP. The interpretation of intrusions in psychosis: An integrative cognitive approach to hallucinations and delusions. Behav Cogn Psychother 2001; 29: 257-76.
21. Morrison AP, Renton JC, Dunn H, Williams S, Bentall RP. Cognitive therapy for psychosis: a formulation-based approach. London: Brunner-Routledge, 2004.
22. Kingdon D, Turkington D. Cognitive therapy for schizophrenia. New York: Guilford Press, 2005.
23. Blackburn IM, James I, Milne D, et al. The revised cognitive therapy scale (CTS-R): psychometric properties. Behav Cogn Psychother 2001; 29: 431-46.
24. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76.
25. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988; 23: 99-110.
26. Haddock G, McCarron J, Tarrier N, Faragher EB. Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med 1999; 29: 879-89.
27. Neil ST, Kilbride M, Pitt L, et al. The Questionnaire about the Process of Recovery (QPR): a research instrument developed in collaboration with service users. Psychosis 2009; 1: 145-55.
28. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101: 323-29.
29. Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997; 35: 785-91.
30. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998; 36: 455-70.
31. Little RJA, Rubin DB. Statistical Analysis with Missing Data. London: John Wiley and Sons, 2002.
32. Leucht S, Kissling W, Davis JM. The PANSS should be rescaled. Schizophr Bull 2010; 36: 461-62.
33. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacology 2007; 32: 1903-10.
34. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry 2011; 168: 286-92.
35. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean? Schizophr Res 2005; 79: 231-38.
36. National Institute for Clinical Excellence. Psychosis and schizophrenia in children and young people: Recognition and management. UK: NICE, 2013.
37. Jones C, Hacker D, Cormac I, Meaden A, Irving CB. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 2012; 4: CD008712.
38. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005; 62: 717-24.